Tissue Chips - Next generation in vitro model for targeted therapeutics
|Organs on a chip|
Nanomaterials, Nanobiotechnology, Health, Tissue Chips, In vitro, Microfluidics, In vivo, Organ Chips
Cancer remains a leading cause of death worldwide. Engineered nanomaterials for the diagnosis and treatment of cancer have attracted enormous interest in past decades, and they hold great promise for cancer therapy due to their unique properties such as nanoscale size, controlled drug release and their potential in targeted delivery. A wide range of nanomaterials have been developed for cancer therapy, ranging from inorganic, organic, polymer particles to lipids, proteins and other synthetic compounds. While only 1318 nanomedicine formulations in the field of cancer therapy entered clinical trials with most of them focusing on marketed products, such as liposomal or albumin-based systems. Currently only four nanoparticle-based drug delivery systems have been approved by the FDA (Doxil, DaunoXome, Marqibo, and Abraxane). This demonstrates the huge gap between laboratory research and clinical translation of drug delivery systems. One of the major challenges is the lack of reliable and fast platforms to evaluate and optimize the large libraries of nanomaterials. Researchers mainly rely on in vitro cell culture and in vivo animal models to evaluate the efficacy of nanomaterials. 2D cell culture systems are simple and convenient, but they are unable to capture the complexity of biological processes. In contrast, animal models have served as valuable platforms to explore the in vivo behaviour of targeting nanomaterials, but they are time-consuming, costly and often fail to recapitulate human organ functions. A number of projects are available that involve the development of tumour-on-a-chip, organs-on-a-chip for rapid preclinical evaluation of potential nanomaterials for targeted therapeutics.
|Lead investigator||Chun-Xia Zhao
|Research group||Centre for Biomolecular Engineering|